

#148 - Richard Miller, M.D., Ph.D.: The gold standard for testing longevity drugs: the Interventions Testing Program
13 snips Feb 8, 2021
Richard Miller, a pathology professor at the University of Michigan and architect of the Interventions Testing Program, dives into the intriguing world of longevity research. He discusses groundbreaking findings on drugs like rapamycin and metformin, shedding light on their effects on lifespan in mice. Miller also explores the myths surrounding aging, the value of negative results from studies, and the nuances of using compounds like acarbose and nicotinamide riboside. His insights challenge conventional views and highlight the complexities of drug testing in the quest for a longer life.
AI Snips
Chapters
Transcript
Episode notes
Hayflick Limit Misconception
- Hayflick observed that normal human cells divide a limited number of times in culture, about 50.
- He mistakenly equated this to aging, influencing research for years.
Telomere Length and Aging
- Telomere length, while important in cancer and evolutionary biology, is not a reliable biomarker for aging.
- Hyperbaric oxygen's effect on telomeres doesn't prove anti-aging benefits.
Unitary Aging Process
- 18 years ago, most scientists didn't believe aging was a single, controllable process.
- Richard Miller argued against this, believing in a unitary aging process that could be slowed.